Yohei Turi Ohno
@OhnoTuri
Followers
633
Following
3K
Media
21
Statuses
833
Valve and Structural Heart Interventional cardiologist, Tokai University School of Medicine, Tweets are my own. Passionate about imaging and hemodynamics.
Tokyo, Japan
Joined March 2019
Are we gonna witness legendary lives this weekend in Tokyo? Definitely maybe! #oasislive25 #Tokyo 🇯🇵
0
0
10
Shohei Ohtani has hit some memorable Postseason home runs. Will he continue to add to his legacy this #WorldSeries? 👀
86
753
7K
How safe and effective is transcatheter ASD closure long term? In a 15-year, 400-patient cohort, closure success reached 99% at 8 years with no erosions or late complications, underscoring the durability of modern nitinol devices. #AHAJournals @rayhaddad
ahajournals.org
0
4
12
無症状の大動脈弁狭窄症、どれくらいの経過を辿る？ 無症状って本当？ マルチモダリティを用いた客観的指標とは？ @Miho_Fukui_
@OhnoTuri THL無料月例ウェビナー：『つながる！大動脈弁狭窄症診療：新時代の治療戦略』 https://t.co/GBYrdEDyFe
@PeatixJPより
tokyoheartlab20251020.peatix.com
大動脈弁狭窄症 (AS: aortic stenosis)の治療体系が、今大きく変わりつつあります。ASは進行性の疾患であり、症状出現後には急速な予後悪化が知られています。これま... powered by Peatix : More than a ticket.
0
1
4
The DOUBLE-TAP study highlighted the value of post-dilatation in TAVI. @dmylotte & Soh discuss how a “double-tap” can optimise THV expansion and outcomes. #TAVI #StructuralHeart Editorial 👉 https://t.co/NhxY0gUZdD Main paper by 👉 https://t.co/OLpHUCpuTA
1
26
68
Can’t agree with you more, Didier @didier_tchetche Obviously the index procedure is the most important and the “optimization” is the key😉
As redo-TAVI highlights constant under expansion of THVs, double TAP is likely to become the default strategy for both BEV and SEV. Better expansion, improved AR and hemodynamics, less pin-wheeling, better durability… Thoughts ? https://t.co/NRuSwcr0Zk
@EuroInterventio
1
0
8
Gearing up for #TCT2025? So are we! @AsherElad, @BiascoDr , @aayshacader, @ANazmiCalik, @CurioJonathan, @DanieleGiacoppo, @mirvatalasnag,@KVM83, @OhnoTuri and @Sticchi_Alex will provide you with the international perspective from this year's TCT in San Francisco.
My top 3 picks for #TCT2025 — not to miss 👇 🚩DCB: SELUTION DeNovo – DCB vs DES for de novo lesions. 🚩 Calcium: Short-CUT – IVL vs cutting. 🚩 INVEST-CTO – planned investment strategy. 🎯 Which of these trial results will impact practice the most?
0
13
25
So happy to witness the legend
Ohtani: I think he’s re-writing the story of baseball not just in LA, but in general. Before too long, we might just see him jump above everyone as the best player to ever play the game. #mlbontbs
0
0
2
Truly legendary and phenomenal unicorn 🦄 👏👏👏
Shohei Ohtani tonight: Hit three home runs Allowed just two hits Pitched six shutout frames Struck out TEN batters Greatest #Postseason performance EVER?
0
0
0
Three milestones ahead for the PCR community! - PCR London Valves (16-18 November) – uncover the Late-Breaking Trials @drmaisano @drtpatterson @nicolo_piazza @didier_tchetche - GulfPCR-GIM (10-11 December) – discover the Programme @DrHaithamAmin @baumbach_a - PCR Tokyo Valves
0
11
23
Great review Mohamed @Mo_A_W, congrats! Will share with my colleagues 😉 @CardiologyTokai
Read our state-of-the-art review for an in-depth understanding of alternative access possibilities for #TAVR #JACCINT @feistritzerH_J
1
0
3
Where are we with drug-coated balloons (DCB) in PCI? Five thoughts. 1) The use of DCB in patients with in-stent restenosis, especially of a bare metal stent, is well established and evidence-based (now also in the US). 2) Conversely, DCB use in de novo disease lacks compelling
13
137
389
👏👏👏💪🔥
0
0
1
いよっ博士！👍
心不全学会も無事に終わり、今週末はいよいよ高血圧学会総会です！ 我々が誇る高血圧専門医、かつ腎動脈/神経の解剖で学位取得の"デナベーション博士"、佐藤 優先生がモーニングセミナー登壇！ スポンサードセッションは通常オンデマンド配信ありません、ぜひ現地でお待ちしています！ #jsh2025
0
0
4
Kentaro Hayashida discusses tricuspid and structural interventions with Jeremy Quah Wu Jin — sharing fresh insights from #AictPCR.
0
6
14
👏👏👏
0
0
1